{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CBLL",
  "name": "CeriBell, Inc.",
  "url": "https://orbyd.app/dossiers/CBLL/",
  "json_url": "https://orbyd.app/dossiers/CBLL.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "August re-rating is reimbursement-driven: CMS granted an NTAP of up to $2,171 per eligible Medicare case for the Ceribell Delirium Monitor on 2026-08-03 (effective 2026-10-01) and FY26 guidance went to $114–117M on 2026-08-10. Narrative ACCELERATING, but the headline sequence is spent — the 2026-08-21 close of $24.20 sits 2.8% under the 52-week high with RSI(14) 86 and CEO/CFO Form 4 sales at ~$25.03 on 2026-08-19.",
  "invalidation_trigger": "A weekly close below $21.50 gives back the August NTAP-and-guidance repricing and undercuts every disclosed insider sale print from 2026-08-13 onward; secondary, the 2026-10-01 NTAP effective date passes and the Q3 call (~2026-11-09, est.) carries no delirium conversion detail.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "managed-care-health-services",
    "binary-catalyst-biotech",
    "ai-datacenter-infrastructure"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Adjusted EBITDA excludes stock-based compensation and other items: Q2 2026 showed a $9.8M adjusted EBITDA loss against a $19.3M GAAP net loss.",
    "The CMS NTAP is a time-limited add-on tied to eligible inpatient cases, not a permanent DRG rate; continuation runs through the annual IPPS rulemaking cycle.",
    "August 2026 executive Form 4 sales were largely executed under Rule 10b5-1 plans; individual prints should be read against the plan adoption dates in the filings.",
    "Delirium monitoring runs on the same cleared headband-and-recorder platform as the seizure product, so a hardware or supply issue would hit both revenue lines.",
    "Listed on Nasdaq since 2024 — fewer than two full years of reported quarters, so seasonality in account adds is not yet established."
  ],
  "body_markdown": "## Current Thesis\nThe August re-rating is reimbursement-driven. On 2026-08-03 CMS granted a New Technology Add-on Payment of up to $2,171 per eligible Medicare inpatient case for the Ceribell Delirium Monitor System, effective 2026-10-01. On 2026-08-10 the company raised FY2026 revenue guidance to $114–117M from $112–116M (consensus $113.979M) and disclosed a further FDA 510(k) clearance for two AI algorithms inside its existing cloud neurology portal. The narrative leg an investor is buying: a second clinical indication that gets funded *before* it launches, sold into the same 712 ICU accounts already running the seizure product, on 92% gross margin. Life-cycle read: ACCELERATING — dated by the 2026-08-03 NTAP, the 2026-08-10 guide raise, and target actions on 2026-08-11 and 2026-08-18.\n\n## Bull Case\n- **Payment precedes launch.** The NTAP (announced 2026-08-03) takes effect 2026-10-01; management has guided the commercial launch of the Delirium Monitoring Solution to Q4 2026 (2026-08-10 call). Hospitals get the economics before the rep asks for the order.\n- **Q2 2026 (reported 2026-08-10):** revenue $28.1M, +33% YoY; product revenue $21.2M (+33%), subscription $6.9M (+30%); 712 active accounts. Growth did not decelerate into the guide raise.\n- **Gross margin 92% in Q2 2026 versus 88% in Q2 2025**, attributed to manufacturing efficiencies, a Vietnam production line and one-time tariff refunds. At that level, incremental revenue converts almost entirely into gross profit.\n- **The 2026-08-10 510(k)** covers epileptiform abnormality detection and artifact reduction delivered through the existing cloud portal — software shipped into an installed base, with no new hardware sale required to monetise it.\n- **Guidance moved more than the beat.** Q2 revenue beat by $0.812M ($28.097M vs $27.285M est.), while the FY midpoint went from $114.0M to $115.5M.\n- **Sell-side followed:** Canaccord Genuity Buy, target to $26 on 2026-08-11; BTIG Buy, target to $30 from $28 on 2026-08-18.\n- **Funding is in place for the launch:** $129.3M in cash and marketable securities at Q2 2026, plus a new credit facility with up to $60M of committed capital. No equity raise has been announced as of 2026-08-22.\n\n## Bear Case\n- **The bottom line missed.** Q2 EPS of $(0.51) against a $(0.47) estimate (2026-08-10). Operating expenses of $45.9M grew 37% YoY against 33% revenue growth — spend is outrunning the top line.\n- **GAAP loss $19.3M versus a $9.8M adjusted EBITDA loss** in the same quarter. The $9.5M difference is what the adjusted figure removes.\n- **The 92% gross margin includes one-time tariff refunds** (management, 2026-08-10). Q3 laps a flattered number.\n- **NTAP sets a payment, not a purchase order.** It is a per-case, time-limited Medicare add-on. Even on the guided Q4 launch, the first meaningful revenue read on delirium arrives with Q4 results in early 2027.\n- **Insiders sold into the move.** Director Joseph M.\n- **The raise was narrow** — $2M at the low end, $1M at the high end — relative to a 28.9% three-month move in the shares.\n- **Target support is thin above here.** The 2026-08-21 close of $24.20 is roughly 7% under Canaccord's $26 and roughly 19% under BTIG's $30; the higher number is one house.\n\n## Setup & Price Structure\n- Last completed daily close $24.20 (2026-08-21), 2.8% below the $24.89 52-week high, with a three-month price change of +28.9% and RSI(14) at 86.0.\n- Insider open-market sales on 2026-08-19 printed a weighted average $25.03 — above the $24.89 52-week closing reference. INFERRED from that: the shares traded through the highest close of the window intraday and have since come back to $24.20.\n- The $23.40 print of 2026-08-13 and the $25.00–$25.03 prints of 2026-08-18/19 bracket the post-earnings August range that is independently visible in filings, which is the cleanest observable structure this name offers without proprietary chart data.\n- Crowding observables, stated plainly: three sell-side target actions inside eight sessions (2026-08-11 Canaccord $26, 2026-08-11 BTIG $28 reiterated, 2026-08-18 BTIG $30); executive and director supply at $23.40–$25.03; RSI(14) 86.0; no earnings date inside 30 days to force a resolution.\n- Nothing in the tape argues SATURATED — coverage is a handful of houses and the delirium indication has not yet produced a revenue dollar. What argues *late in this leg* is the overbought reading arriving simultaneously with the end of the headline sequence.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-22 → 2026-09-21: no confirmed company-dated event.** September conference participation had not been announced as of 2026-08-22; the pattern is short notice (the 2026-08-12 Canaccord fireside chat was announced 2026-07-28).\n- **2026-10-01 (outside the window):** NTAP effective date. The first day an eligible Medicare inpatient case can carry the up-to-$2,171 add-on.\n- **~2026-11-09 (est., outside the window):** Q3 2026 results. Reporting cadence in 2026 has been 2026-02-24 (Q4'25), 2026-05-11 (Q1'26), 2026-08-10 (Q2'26).\n\n## Elapsed catalysts\n\n- **Q4 2026 (est., outside the window):** guided commercial launch of the Delirium Monitoring Solution. No day-level date announced as of 2026-08-22. *(passed 1d ago)*\n\n## What Would Change Our Mind\nThe fundamental break is account adds stalling. 712 active accounts at Q2 2026 is the number the next print has to beat convincingly; a Q3 report that shows the account base compounding at a slower clip while FY2026 guidance of $114–117M is merely reaffirmed would mean the delirium option is being paid for with no evidence behind it yet. A Q3 gross margin below 90% would confirm that the 92% print was carried by one-time tariff refunds rather than mix.\n\nOn price, a weekly close below $21.50 would mark the August repricing as given back — that level sits under every insider sale print disclosed between 2026-08-13 and 2026-08-19 and more than 10% under the 2026-08-21 close of $24.20. Separately, if 2026-10-01 comes and goes and the Q3 call (~2026-11-09, est.) carries no delirium conversion or unit detail, the reimbursement leg becomes a 2027 story that the current multiple has to carry unaided.\n\nThe other direction matters too: a Q3 print with account adds accelerating past the Q2 pace, gross margin holding at or above 90% without tariff help, and any quantified delirium pipeline would extend the leg rather than end it.\n\n## Correlation Notes\n- CBLL behaves as unprofitable high-growth medtech: 33% revenue growth with a $19.3M quarterly GAAP loss makes the shares sensitive to small-cap growth risk appetite and to rate expectations, more than to the medical-device majors.\n- The shared policy factor with any NTAP-dependent device is the annual CMS IPPS rulemaking cycle, which determines whether a temporary add-on persists or lapses into base DRG payment.\n- The shared demand factor with other point-of-care ICU monitoring names is hospital capital and staffing budgets, not procedure volume in elective settings.\n- Despite the 2026-08-10 AI-algorithm clearance, the revenue driver is reimbursement and hospital budgets; INFERRED, the name should not be expected to track AI-infrastructure flows.\n- No direct commodity linkage. Tariff exposure enters through manufacturing (the Vietnam line cited on 2026-08-10) and shows up as a gross-margin input rather than a demand variable.",
  "first_seen": "2026-08-21",
  "last_analyzed": "2026-08-22T07:10:59+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}